AstraZeneca's Soliris has become the first approved treatment in the EU for children and adolescents with generalised myasthenia gravis, a disorder that causes weakness in
The FDA has become the first global regulator to approve UCB’s Rystiggo, a treatment for generalised myasthenia gravis that the company says is the only drug that can be u
The market for drugs to treat the muscle-wasting disease generalised myasthenia gravis (gMG) is getting more crowded, and Argenx has just claimed an FDA approval that coul
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
One of the main assets of Sanofi's $3.7 billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl